Platelets and Cancer-Associated Thrombosis

Connolly, Gregory C.; Phipps, Richard P.; Francis, Charles W.

doi:10.1053/j.seminoncol.2014.04.009

Cited by 53 publications

(44 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…26 In addition, VTE was associated with thrombocytosis (Table 2), which has recently been recognized in the oncology field. 27 Our findings also showed that elevated IL-6 is associated with thrombocytosis, and those with advanced-OCCC had the highest frequency of multiple-site VTE (DVE+PE; 11.3%) compared with the other groups.…”

Section: Discussionsupporting

confidence: 62%

Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma

Matsuo¹,

Hasegawa²,

Yoshino³

et al. 2015

European Journal of Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 62%

Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma

Matsuo¹,

Hasegawa²,

Yoshino³

et al. 2015

European Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Interestingly, there is clinical evidence for the involvement of platelets in cancer-associated thrombosis [55]. For instance, thrombocytosis is a risk factor for VTE in cancer patients, many of whom have increased plasma markers of platelet activation [56][57][58][59][60][61].…”

Section: Discussionmentioning

confidence: 99%

Tissue factor–positive tumor microvesicles activate platelets and enhance thrombosis in mice

Geddings

Hisada

Boulaftali

et al. 2016

Journal of Thrombosis and Haemostasis

139

144

View full text Add to dashboard Cite

Background Cancer patients have an approximately four-fold increased risk of venous thromboembolism (VTE) compared with the general population, and cancer patients with VTE have reduced survival. Tumor cells constitutively release small membrane vesicles called microvesicles (MVs) that may contribute to thrombosis in cancer patients. Clinical studies have shown that levels of circulating tumor-derived, tissue factor-positive (TF+) MVs in pancreatic cancer patients are associated with VTE. Objectives We tested the hypothesis that TF+ tumor-derived MVs (TMVs) activate platelets in vitro and in mice. Materials and Methods We selected two human pancreatic adenocarcinoma cell lines expressing high (BxPc-3) and low (L3.6pl) levels of TF as models to study the effect of TF+ TMVs on platelets and thrombosis. Results and Conclusions We found that both types of TF+ TMVs activated human platelets and induced aggregation in vitro in a TF- and thrombin-dependent manner. Further, injection of BxPc-3 TF+ TMVs triggered platelet activation in vivo and enhanced thrombosis in two mouse models of venous thrombosis in a TF-dependent manner. Importantly, BxPc-3 TF+ TMV-enhanced thrombosis was reduced in Par4-deficient mice and in wild-type mice treated with clopidogrel, suggesting that platelet activation was required for enhanced thrombosis. These studies suggest that TF+ TMV-induced platelet activation contributes to thrombosis in cancer patients.

show abstract

“…It was reported previously that enlarged platelets were metabolically more active and reflect higher thrombogenic potential [ 19 ]. The high platelet count was found to be associated with an elevated risk of cancer-associated thrombosis [ 16 , 17 ]. However, their role in myxoma-related embolism is still uncertain.…”

Section: Discussionmentioning

confidence: 99%

Risk Factors for Embolism in Cardiac Myxoma: A Retrospective Analysis

Zhang

Liang

et al. 2015

Med Sci Monit

View full text Add to dashboard Cite

BackgroundMyxomas are the most common primary heart tumors and are closely associated with embolic events. Cardiac myxomas typically arise from the interatrial septum at the border of the fossa ovalis in the left atrium. Any other location is considered atypical. Embolism, one of the complications of myxoma, is associated with high morbidity and mortality. The aim of this study was to investigate the risk factors for embolism in patients with cardiac myxoma.Material/MethodsIn this retrospective study, a cohort of 162 patients with cardiac myxomas was surgically treated between January 1998 and June 2014 at 3 cardiac centers in China. Preoperative data, including platelet count, sex, age, and the tumor (size, location, surface, and attachment), were compared between embolic and non-embolic groups of patients.ResultsNo significant differences in vascular risk factors were seen between the 2 groups. However, the percentage of higher platelet count (>300×109/L) and mean platelet volume in the embolic group were significantly higher than in the non-embolic group (P=0.0356, and 0.0113, respectively). Irregular surface and atypical location of the myxomas were also independently associated with increased risk of embolic complications.ConclusionsTumor location, macroscopic appearance, mean platelet volume, and high platelet count are strong risk factors for embolic events in patients with cardiac myxomas.

show abstract

Platelets and Cancer-Associated Thrombosis

Cited by 53 publications

References 60 publications

Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma

Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma

Tissue factor–positive tumor microvesicles activate platelets and enhance thrombosis in mice

Risk Factors for Embolism in Cardiac Myxoma: A Retrospective Analysis

Contact Info

Product

Resources

About